rWGS^® is best considered for critically-ill infants and children in the inpatient setting for which a rapid genetic diagnosis could impact medical management and outcomes.

Indications for rWGS^® testing include:

• Critically-ill infants and children in the intensive care unit with no unifying diagnosis
• Critically-ill infants and children for whom a rapid molecular diagnosis may inform medical management, treatment and/or prognosis
• Molecular diagnosis of suspected genetic disease
  •Identification of rare genetic disease variants in patients who have failed to receive a diagnosis despite extensive work-up and previous testing
• Infants and children with a history of multiple hospitalizations or readmission within 30 days of discharge for an unexplained condition
• Infants or children with prolonged hospital stay

Benign and Likely Benign variants are not reported. In addition, RCIGM-CGC does not offer reporting on carrier status, pharmacogenetic markers, polygenic risk scores, or genome wide association studies (GWAS) risk variants.